Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Standiford Helm

Interventional Pain Medicine Orange, CA Medical Doctor

NPI 1437156627 CMS profile 200366

101 The City Dr S, Orange, CA 92868

Open in the dashboard

General payments

$254,336

167 records reported · program years 2019–2025

Research payments

$378

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$47,188

5 holdings reported · through program year 2025

Research they led as principal investigator

$221,215 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Standiford Helm of Orange, CA is reported in the CMS Open Payments database as having received $254,336 across 167 general payments and $378 in research payments paid to them. Separately, studies naming them as principal investigator received $221,215 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $47,188 across 5 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,542 23
2024 General $171 2
2023 General $5,973 4
2022 General $239,490 5
2021 General $335 17
2020 General $704 42
2020 Research $378 1
2019 General $1,121 74
2023 Ownership $0 1
2022 Ownership $0 1
2021 Ownership $23,538 1
2020 Ownership $23,538 1
2019 Ownership $111 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Standiford Helm
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Standiford Helm were reported at $6,542. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Standiford Helm Interventional Pain Medicine median Middle half National median
2019 $1,121 $684 $216–$2,079 $163
2020 $704 $382 $122–$1,109 $114
2021 $335 $552 $167–$1,554 $132
2022 $239,490 $605 $187–$1,924 $149
2023 $5,973 $671 $195–$1,915 $160
2024 $171 $684 $206–$1,837 $164
2025 $6,542 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Curonix LLC $248,863 29 payments
  2. Stimwave Technologies Incorporated $3,204 5 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $368 23 payments
  4. Collegium Pharmaceutical, Inc. $232 20 payments
  5. Scilex Pharmaceuticals Inc. $224 13 payments
  6. Sentynl Therapeutics, Inc. $157 11 payments
  7. Biodelivery Sciences International, Inc. $138 10 payments
  8. AbbVie, Inc. $132 3 payments
  9. Allergan Inc. $95 5 payments
  10. Lilly USA, LLC $75 4 payments
  11. Other $848 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Acquisitions $236,250 1 payment
  2. Consulting Fee $15,395 28 payments
  3. Food and Beverage $2,691 138 payments
Products named General payments · program years 2019–2025
  1. StimQ Freedom-8A Receiver Kit Channel A US w/ Receiver $239,390 4 payments
  2. StimQ Receiver Stimulator Kit Channel A US w/Receiver $239,390 4 payments
  3. Freedom-4A Receiver Kit Channel A US w/ Receiver $239,390 4 payments
  4. Freedom-8A Receiver Kit Channel A US w/ Receiver $239,390 4 payments
  5. StimQ Freedom-4A Receiver Kit Channel A US w/ Receiver $239,390 4 payments
  6. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $12,613 28 payments
  7. RELISTOR $317 19 payments
  8. XTAMPZA $211 19 payments
  9. Levorphanol Tartrate $157 11 payments
  10. ZTLido $129 8 payments
  11. Other $1,772 94 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Purdue Pharma L.P. $378 1 payment

Records

168 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record